Noguchi S, Shuin T, Kubota Y, Masuda M, Yao M, Hosaka M
Department of Urology, Yokohama City University School of Medicine.
Hinyokika Kiyo. 1995 Jul;41(7):517-20.
Between May 1990 and April 1994, eleven patients with metastatic renal cell carcinoma received a combination therapy with interferon-alpha (IFN alpha) and 5-fluorouracil (5FU). IFN was administered intramuscularly six or ten million units three times per week for 4 weeks and 300 mg/m2 of 5FU was administered by continuous intravenous infusion daily for 4 weeks. Of 8 evaluable patients, two had a partial response (25%) two had a minor response (25%), and two had a stable disease (25%). The common side effects of the regimen were flu-like symptoms (91%), mucositis (64%) and leukopenia (75%). Three patients refused this therapy because of severe mucositis or stomatitis. Although the combination of IFN and 5FU in patients with metastatic renal cell carcinoma had some efficacy, this regimen had severe toxicity especially for the gastrointestinal (GI) tract. None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU. The dose limiting factor of this regimen is considered to be GI symptoms.
1990年5月至1994年4月期间，11例转移性肾细胞癌患者接受了α-干扰素（IFNα）与5-氟尿嘧啶（5FU）的联合治疗。IFN通过肌肉注射给药，每周3次，每次600万或1000万单位，共4周；5FU以300mg/m²的剂量每日持续静脉输注，共4周。在8例可评估的患者中，2例出现部分缓解（25%），2例出现轻度缓解（25%），2例病情稳定（25%）。该治疗方案的常见副作用包括流感样症状（91%）、粘膜炎（64%）和白细胞减少（75%）。3例患者因严重的粘膜炎或口腔炎而拒绝该治疗。尽管IFN与5FU联合治疗对转移性肾细胞癌患者有一定疗效，但该方案有严重毒性，尤其是对胃肠道。没有患者能够接受最初计划的500mg/m²的5FU剂量。该方案的剂量限制因素被认为是胃肠道症状。
